Katyayani (Katya) Papatla, MD, MPH
she/her/hers
Assistant Professor of Obstetrics, Gynecology and Reproductive SciencesCards
About
Research
Publications
2025
Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study
Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study. International Journal Of Gynecological Cancer 2025, 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.Peer-Reviewed Original ResearchPlatinum-based chemotherapyPlatinum-based groupNon-platinum-based regimensOvarian carcinosarcomaCytoreductive surgeryOverall survivalRetrospective two-center cohort studyStage III to IV diseaseAdjuvant platinum-based chemotherapyMalignant mixed Mullerian tumorPlatinum-based chemotherapy regimensCox proportional hazards regression model analysisKaplan-Meier survival curvesMedian overall survivalMixed mullerian tumorsOptimal cytoreductive surgeryTwo-center cohort studyStandard chemotherapy regimenAdvanced-stage diseaseLog-rank testRetrospective chart reviewFirst-line approachYale-New Haven HospitalMulti-institutional studyNon-inferiority designA phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses
Ettorre V, Bellone S, Greenman M, McNamara B, Palmieri L, Sethi N, Demirkiran C, Papatla K, Kailasam A, Siegel E, Ratner E, Santin A. A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses. Gynecologic Oncology 2025, 197: 110-115. PMID: 40334308, DOI: 10.1016/j.ygyno.2025.04.591.Peer-Reviewed Original ResearchProgression free survivalWhole-exome sequencingImmune checkpoint inhibitorsOverall survivalEndometrial cancerMicrosatellite instability-highCheckpoint inhibitorsFree survivalFollow-upResponse to immune checkpoint inhibitorsPatients treated with pembrolizumabProspective phase II studyExome sequencingResponse rateRecurrent platinum-resistantPhase II studyPhase 2 trialOverall survival dataEndometrial cancer patientsMLH-1MSI-H patientsFoundationOne platformImproved OSUpdate survivalPrognostic significancePreclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.
Greenman M, Demirkiran C, Bellone S, Hartwich T, McNamara B, Ettorre V, Santin N, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin A. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. Cancer Research Communications 2025, 5: 774-782. PMID: 40299780, PMCID: PMC12062949, DOI: 10.1158/2767-9764.crc-25-0057.Peer-Reviewed Original ResearchConceptsTrophoblast cell surface antigen 2Uterine serous carcinomaAntibody-dependent cell-mediated cytotoxicityAntibody-drug conjugatesCell-mediated cytotoxicitySerous carcinomaPreclinical activityCell linesTargets trophoblast cell-surface antigen-2Presence of peripheral blood lymphocytesTreatment of uterine serous carcinomaInduce antibody-dependent cell-mediated cytotoxicityPrimary USC cell linesRecurrent uterine serous carcinomaUSC xenograftsUterine serous carcinoma cell linesAntigen 2In vivoPrimary tumor cell linesTROP2 overexpressionBiomarker-targeted therapiesControl ADCChromium release assayHigher recurrence rateTumor growth suppression
2024
Mitigating disparity?: Treatment patterns, survival, and recurrence rates by race, ethnicity, and hospital site across a large urban health system
Papatla K, Orfanelli T, Stoffels G, Layne T, Baldwin E, Leibold A, Blank S, Cohen S. Mitigating disparity?: Treatment patterns, survival, and recurrence rates by race, ethnicity, and hospital site across a large urban health system. Gynecologic Oncology Reports 2024, 53: 101372. PMID: 38584803, PMCID: PMC10997945, DOI: 10.1016/j.gore.2024.101372.Peer-Reviewed Original ResearchSocial determinantsHealth systemHospital sitesSocial determinants of healthUrban academic health systemPalliative care referralDeterminants of healthRetrospective chart reviewRates of chemotherapy completionUrban health systemAcademic health systemBlack patientsChemotherapy completion ratePatterns of careEndometrial cancerAll-Cause MortalityRates of all-cause mortalityAssociated with racePalliative careCare referralRacial disparitiesSystem hospitalsDescriptive statisticsRecurrence rateBlack women
2022
2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage
Velasquez J, Papatla K, Kaplowitz E, Coughlin A, Zachem A, Goldberger C, Blank S. 2022-RA-631-ESGO The impact of COVID 19 on cervical cancer screening and triage. International Journal Of Gynecological Cancer 2022, 32: a374-a375. DOI: 10.1136/ijgc-2022-esgo.803.Peer-Reviewed Original Research
2021
COVID-19 and Gynecologic Oncology: What Have We Learned?
Leibold A, Papatla K, Zeligs K, Blank S. COVID-19 and Gynecologic Oncology: What Have We Learned? Current Treatment Options In Oncology 2021, 22: 117. PMID: 34812973, PMCID: PMC8609172, DOI: 10.1007/s11864-021-00905-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCaregivers providing careImpact of COVID-19Gynecologic oncologyGynecologic cancerTreatment of womenGynecologic oncology patientsCancer careGYN cancersHealthcare systemEquitable distribution of resourcesPatient's abilityEquitable distributionOverutilized resourcesCareCOVID-19Practice medicineOncology patientsMedical practitionersGroup of patientsLong-term outcomesGynecologic oncologistsOncologyCOVID-19 victimsCOVID-19 pandemicWomen
2019
Second primary anal and oropharyngeal cancers in cervical cancer survivors
Papatla K, Halpern M, Hernandez E, Brown J, Benrubi D, Houck K, Chu C, Rubin S. Second primary anal and oropharyngeal cancers in cervical cancer survivors. American Journal Of Obstetrics And Gynecology 2019, 221: 478.e1-478.e6. PMID: 31128108, DOI: 10.1016/j.ajog.2019.05.025.Peer-Reviewed Original ResearchConceptsCervical cancer survivorsCancer survivorsCervical cancer diagnosisHuman papilloma virus infectionCancer diagnosisVirus-related malignanciesOropharyngeal cancerAnal cancerPapilloma virus infectionStandardized incidence ratioSquamous cell carcinomaHealth care providersOropharyngeal cancer riskCervical cancerIncidence of cervical cancerRisk of anal cancerPopulation-based cohortCell carcinomaIncidence ratiosCare providersOPC riskCancer riskCenters for Disease ControlHistory of squamous cell carcinomaVirus infectionSecond primary uterine malignancies after radiation therapy for cervical cancer
Papatla K, Houck K, Hernandez E, Chu C, Rubin S. Second primary uterine malignancies after radiation therapy for cervical cancer. Archives Of Gynecology And Obstetrics 2019, 300: 389-394. PMID: 31069490, DOI: 10.1007/s00404-019-05187-9.Peer-Reviewed Original ResearchConceptsEndometrial cancer diagnosisClear-cell adenocarcinomaTreatment of cervical cancerEndometrial cancerCervical cancerRadiation therapyHistological typeConclusionA small proportionUterine malignanciesCancer diagnosisHistologic type of endometrial cancerRisk of uterine malignancyEnd Results Program databasePrimary uterine malignancyAggressive histological typeMethodsA population-based cohortPrimary endometrial cancerEndometrial cancer patientsHistological type distributionDiagnosis of cervical cancerPopulation-based cohortProportion of womenPurposeRadiation exposurePelvic radiationVaginal bleeding
2018
Prevention and Early Identification of Urinary Tract Injury During Minimally Invasive Surgery
Papatla K, Brown J, Houck K. Prevention and Early Identification of Urinary Tract Injury During Minimally Invasive Surgery. Topics In Obstetrics & Gynecology 2018, 38: 1-7. DOI: 10.1097/01.pgo.0000529674.16591.cc.Peer-Reviewed Original Research
2017
Gestational Trophoblastic Neoplasia
Jordan S, Papatla K, Hernandez E. Gestational Trophoblastic Neoplasia. Topics In Obstetrics & Gynecology 2017, 37: 1-5. DOI: 10.1097/01.pgo.0000515499.17019.78.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Katyayani (Katya) Papatla, MD, MPH, is a gynecologic oncologist specializing in cancers of the female reproductive system, including ovarian, uterine, cervical, vulvar, and vaginal cancers.
Dr. Papatla is dedicated to supporting her patients and finds inspiration in their strength and resilience. "It is such a privilege to share this journey with my patients, and I am constantly inspired by their stories," she says.
She advises women to be vigilant about their health, encouraging annual gynecological visits and prompt attention to symptoms such as postmenopausal bleeding, persistent abdominal pain, or unexpected weight loss. "Don't be afraid to listen to your body and see your physician if something feels off,” she says.
Dr. Papatla received her medical degree and a master's in public health from the University of Miami Miller School of Medicine. She completed her residency at Temple University Hospital and a fellowship in gynecologic oncology at the Icahn School of Medicine at Mount Sinai. She is an assistant professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine.
Clinical Specialties
Gynecology; Minimally Invasive Gynecology
Fact Sheets
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale MedicineUterine Sarcoma
Learn More on Yale MedicineUterine Cancer
Learn More on Yale Medicine
Board Certifications
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 2024
Yale Medicine News
News
News
- April 21, 2025
Yale Cancer Center Research Breakthroughs Unveiled at AACR Annual Meeting
- March 20, 2025
Smilow Cancer Hospital Gynecologic Oncology Expertise in Fairfield County
- November 07, 2024
Yale Ob/Gyn Faculty Present the Latest in Gynecologic Oncology at Memorial Conference
- September 27, 2024
Katyayani (Katya) Papatla, MD/MPH, in honor of Gynecologic Cancer Awareness Month
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.